跳到主要导航 跳到搜索 跳到主要内容

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

  • Yuxiao Song
  • , Yang Fu
  • , Qi Xie
  • , Bo Zhu
  • , Jun Wang*
  • , Bicheng Zhang*
  • *此作品的通讯作者
  • Hubei Univ Chinese Med
  • Shandong First Med Univ
  • Army Med Univ

科研成果: 期刊稿件 › 综述 › 同行评审

247 引用 (Scopus)

摘要

Advances in cancer immunity have promoted a major breakthrough in the field of cancer therapy. This is mainly associated with the successful development of immune checkpoint inhibitors (ICIs) for multiple types of human tumors. Blockade with different ICIs, including programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, may activate the immune system of the host against malignant cells. However, only a subgroup of patients with cancer would benefit from immune checkpoint blockade. Some patients experience primary resistance to initial immunotherapy, and a majority eventually develop acquired resistance to ICIs. However, the mechanisms involved in the development of drug resistance to immune checkpoint blockade remain unclear. Recent studies supported that combination of ICIs and anti-angiogenic agents could be a promising therapeutic strategy for overcoming the low efficacy of ICIs. Moreover, through their direct anti-cancer effect by inhibiting tumor growth and metastasis, anti-angiogenic drugs reprogram the tumor milieu from an immunosuppressive to an immune permissive microenvironment. Activated immunity by immune checkpoint blockade also facilitates anti-angiogenesis by downregulating the expression of vascular endothelial growth factor and alleviating hypoxia condition. Many clinical trials showed an improved anti-cancer efficacy and prolonged survival following the addition of anti-angiogenic agents to ICIs. This review summarizes the current understanding and clinical development of combination therapy with immune checkpoint blockade and anti-angiogenic strategy.
源语言英语
期刊论文编号1956
页数17
期刊FRONTIERS IN IMMUNOLOGY
卷11
DOI
出版状态已出版 - 25 8月 2020

基金资助

This research was funded by the National Nature Science Foundation of China (Nos. 81272619 and 81572875), Natural Science Foundation of Hubei Province (2019CFB635), Health Commission of Hubei Province (WJ2019M194), CSCOHengrui Cancer Research Foundation (Y-HR2018-328), and CSCO-BMS Cancer Immunotherapy Research Foundation (Y-BMS2019-003).

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

关键词

  • immune checkpoint inhibitor
  • PD-1
  • PD-L1
  • anti-angiogenesis
  • tumor microenvironment
  • combination therapy

收录

  • SCIE
  • Scopus

学术指纹

探究 'Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment' 的科研主题。它们共同构成独一无二的学术指纹。

引用此